“In 2025, we expect important progress across our inhibitor and degrader programs. Our highly selective SMARCA2 inhibitor, FHD-909, continues to enroll and dose patients in a Phase 1 trial for ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

The international consulting firm Clarivate makes its bet among the novelties ready for the medicine cabinet this year: three ...

The Fatima bint Mubarak Center at Cleveland Clinic Abu Dhabi, part of the M42 group, becomes the first center in the GCC ...

Olema Oncology is a clinical-stage biopharmaceutical company committed to transforming the standard of care and improving outcomes for patients living with breast cancer and beyond. Olema is advancing ...

Paolo Tarantino, MD, PhD, discusses the approval of the oral therapy elacestrant for patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with ESR1 mutations.

DelveInsight’s, “Metastatic Breast Cancer Pipeline Insight” report provides comprehensive insights about 100+ companies and ...

Guggenheim analyst Michael Schmidt maintained a Buy rating on Zentalis Pharmaceuticals (ZNTL – Research Report) yesterday and set a price ...

Morgan Stanley analyst Michael Ulz has maintained their neutral stance on ZNTL stock, giving a Hold rating yesterday.Invest with Confidence: ...

This protein degrader program is now in clinical testing in two different indications,” said Dr. Ying Luo, Chairman and CEO of Cullgen. “Cullgen has successfully generated a portfolio of multiple, ...

Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801, United States Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, ...